Room for improvement: enforcing data exclusivity provisions in Mexico
Data exclusivity is usually discussed in academic circles, mainly due to enforcement complexities and when cases are brought against the Federal Commission for the Protection against Sanitary Risks, the government branch in charge of issuing of marketing authorisations for drugs and agrichemicals.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
25 June 2026 The Federal Circuit has brought Paxloid’s infringement case to an end, serving as a reminder that even minor changes to patent language can have major consequences.
17 June 2026 A cancer diagnostics company has lost its bid to overturn a jury verdict in a major patent dispute that has also spawned parallel proceedings before the Federal Circuit and PTAB.